MYH7 p.(Arg1712Gln) is pathogenic founder variant causing hypertrophic cardiomyopathy with overall relatively delayed onset

The European Reference Network for Rare and Low Prevalence Complex Diseases of the Heart, Luisa Marsili, Freyja H.M. van Lint, Francesco Russo, Karin Y. van Spaendonck-Zwarts, Flavie Ader, Marie Line Bichon, Laurence Faivre, Arjan C. Houweling, Bertrand Isidor, Ronald H. Lekanne Deprez, Moniek G.P.J. Cox, Arthur A.M. Wilde, Benoit Mazel, Sandra Mercier, Dennis Dooijes, Gilles Millat, Karine Nguyen, Jan G. Post, Pascale RichardIrma van de Beek, Alexa M.C. Vermeer, Ludolf Boven, Jan D.H. Jongbloed, J. Peter van Tintelen*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)
16 Downloads (Pure)

Abstract

Introduction: The MYH7 c.5135G > A p.(Arg1712Gln) variant has been identified in several patients worldwide and is classified as pathogenic in the ClinVar database. We aimed to delineate its associated phenotype and evaluate a potential founder effect.

Methods: We retrospectively collected clinical and genetic data of 22 probands and 74 family members from an international cohort.

Results: In total, 53 individuals carried the MYH7 p.(Arg1712Gln) variant, of whom 38 (72%) were diagnosed with hypertrophic cardiomyopathy (HCM). Mean age at HCM diagnosis was 48.8 years (standard deviation: 18.1; range: 8–74). The clinical presentation ranged from asymptomatic HCM to arrhythmias (atrial fibrillation and malignant ventricular arrhythmias). Aborted sudden cardiac death (SCD) leading to the diagnosis of HCM occurred in one proband at the age of 68 years, and a family history of SCD was reported by 39% (5/13) probands. Neither heart failure deaths nor heart transplants were reported. Women had a generally later-onset disease, with 14% of female carriers diagnosed with HCM at age 50 years compared with 54% of male carriers. In both sexes, the disease was fully penetrant by age 75 years. Haplotypes were reconstructed for 35 patients and showed a founder effect in a subset of patients.

Conclusion: MYH7 p.(Arg1712Gln) is a pathogenic founder variant with a consistent HCM phenotype that may present with delayed penetrance. This suggested that clinical follow-up should be pursued after the seventh decade in healthy carriers and that longer intervals between screening may be justified in healthy women < 30 years.

Original languageEnglish
Pages (from-to)300-307
Number of pages8
JournalNetherlands Heart Journal
Volume31
Issue number7-8
DOIs
Publication statusPublished - Aug-2023

Keywords

  • Cardiomyopathy
  • Founder mutation
  • Hypertrophic cardiomyopathy
  • MYH7
  • Myosin heavy chain 7

Cite this